Navigation Links
JCI early table of contents for Aug. 15, 2013

Biomarkers predict time to ovarian cancer recurrence

Ovarian cancer often remains undetected until it is at an advanced stage. Despite positive responses to initial treatment, many patients are at risk of tumor recurrence. A multitude of genetic markers have been implicated in ovarian cancer prognosis. However, the genetic testing required is not practical or affordable in a clinical setting. In this issue of the Journal of Clinical Investigation, Roel Verchaak and colleagues at the MD Anderson Cancer Center identify protein biomarkers that are predictive for time of ovarian cancer recurrence and develop a PRotein-driven index of OVARian cancer (PROVAR). Using PROVAR, the authors were able to discriminate between patients with high and low risk of cancer recurrence, as well as short-term and long-term survival prognosis. In combination with genetic diagnosis, analysis of protein biomarkers may be useful in predicting outcome and determining a treatment plan for ovarian cancer patients.

TITLE: Predicting Time to Ovarian Carcinoma Recurrence Using Protein Markers

MD Anderson Cancer Center, Houston, TX, USA
Phone: 7135632293; E-mail:

View this article at:

A molecule involved in development of chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease (COPD) is characterized by poor airflow due to the breakdown of lung tissue, mucus accumulation and airway dysfunction. Development of COPD is most commonly associated with smoking tobacco, however, it also occurs after acute respiratory infections such as influenza. It is unclear how prior lung disease leads to COPD. In the current issue of the Journal of Clinical Investigation, Michael Holtzman and colleagues at the Washington University School of Medicine report that expression of an inflammatory molecule, interleukin-33 (IL-33), is increased in the airways of both a mouse model of viral-induced COPD and humans with COPD. Increased IL-33 was associated with an increase in mucus production, and expression of other COPD-implicated genes. The authors found in their mouse model that expression of the gene encoding IL-33 was localized to a population of lungs cells that were induced in the airway after viral infection. These results lay the groundwork for potential therapeutic strategies aimed at preventing COPD after acute lung infection.

TITLE: Long-term IL-33-producing epithelial progenitor cells in chronic obstructive lung disease

AUTHOR CONTACT: Michael Holtzman
Washington University School of Medicine, St. Louis, MO, USA
Phone: 314-362-8970; Fax: 314-362-9002; E-mail:

View this article at:


TITLE: Intestinal Epithelial Vitamin D Receptor Signaling Inhibits Experimental Colitis

The University of Chicago, Chicago, IL, USA
Phone: 773-702-2477; Fax: 773-702-2281; E-mail:

View this article at:

TITLE: Fanconi anemia signaling network regulates the spindle assembly checkpoint

Indiana University, Indianapolis, IN, USA
Phone: 317-278-9290; Fax: 317-274-8679; E-mail:

View this article at:

TITLE: Schnurri-3 regulates ERK downstream of WNT signaling in osteoblasts

Weill Cornell Medical College, New York, NY, USA
Phone: 212-746-2078; Fax: 212-746-9215; E-mail:

View this article at:

TITLE: Differentiation and functional regulation of human fetal NK cells

AUTHOR CONTACT: Jakob Michaelsson
Karolinska Institutet, Stockholm, UNK, SWE
Phone: +46 763142535; E-mail:

View this article at:

TITLE: Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy

Genentech, Inc., South San Francisco, CA, USA
Phone: 650-467-7381; Fax: 650-225-6412; E-mail:

View this article at:


Contact: Corinne Williams
Journal of Clinical Investigation

Related biology technology :

1. Netsmart Clients to Receive Nearly $2 Million in Meaningful Use EHR Incentive Payments
2. Access BridgeGap Ventures to Focus on Early-Stage Therapeutic Opportunities
3. VisionGate Uses $2.6 Million NIH Grant to Achieve Full Automation of Cell-CTâ„¢ 3D Imaging System for Early Diagnosis of Cancer
4. Sequenom Announces 2011 Operational Highlights and Early 2012 Outlook
5. CSL Behring Study Confirms Early Treatment with Berinert® Provides Faster Resolution of Acute Hereditary Angioedema Symptoms
6. Corporate Venturing and Early-Stage Financing in the Spotlight at BioTrinity
7. Butamax Early Adopters Group surpasses capacity targets with addition of Big River; Membership represents 11 production facilities and nearly 900 million gallons of ethanol capacity
8. Researchers peek at the early evolution of sex chromosomes
9. Discuss Early Results of the DIAN Trial at CBIs 6th Annual Alzheimers Drug Development Summit
10. Early career distinction: Prestigious award recognizes physicists work in electron dynamics
11. JCI early table of contents for Sept. 4, 2012
Post Your Comments:
(Date:11/24/2015)... 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ... New York on Wednesday, December 2 at 9:30 ... president and CEO, will provide a corporate overview. th ... at 1:00 p.m. ET/10:00 a.m. PT . Jim ... provide a corporate overview. --> th Annual Oppenheimer ...
(Date:11/24/2015)... Worcester, Mass. (PRWEB) , ... November 24, 2015 ... ... need to maintain healthy metabolism. But unless it is bound to proteins, copper ... Institutes of Health (NIH), researchers at Worcester Polytechnic Institute (WPI) will conduct a ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... IIROC on behalf of the Toronto Stock Exchange, confirms ... there are no corporate developments that would cause the ... --> --> About Aeterna Zentaris ... . --> Aeterna Zentaris is a specialty ...
(Date:11/24/2015)... , November 24, 2015 ... new market research report "Oligonucleotide Synthesis Market by Product ... (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical ... published by MarketsandMarkets, the market is expected to reach ... in 2015, at a CAGR of 10.1% during the ...
Breaking Biology Technology:
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
(Date:10/29/2015)... ANN ARBOR, Mich. , Oct. 29, 2015 ... with Eurofins Genomics for U.S. distribution of its ... DNA-seq kit and Rubicon,s new ThruPLEX Plasma-seq ... DNA to enable the preparation of NGS libraries ... in plasma for diagnostic and prognostic applications in ...
(Date:10/27/2015)... Munich, Germany , ... (ASGM) automatically maps data from mobile eye tracking videos ... so that they can be quantitatively analyzed with SMI,s ... Germany , October 28-29, 2015. SMI,s Automated Semantic ... eye tracking videos created with SMI,s Eye Tracking ...
Breaking Biology News(10 mins):